143 related articles for article (PubMed ID: 34991424)
21. Targeted delivery of epirubicin to cancerous cell using copper sulphide nanoparticle coated with polyarginine and 5TR1 aptamer.
Alizadeh F; Yaghoobi E; Imanimoghadam M; Ramezani M; Alibolandi M; Abnous K; Taghdisi SM
J Drug Target; 2023 Dec; 31(9):986-997. PubMed ID: 37869893
[TBL] [Abstract][Full Text] [Related]
22. Improved oral efficacy of epirubicin through polymeric nanoparticles: pharmacodynamic and toxicological investigations.
Tariq M; Alam MA; Singh AT; Panda AK; Talegaonkar S
Drug Deliv; 2016 Oct; 23(8):2990-2997. PubMed ID: 26800371
[TBL] [Abstract][Full Text] [Related]
23. Double targeting and aptamer-assisted controlled release delivery of epirubicin to cancer cells by aptamers-based dendrimer in vitro and in vivo.
Taghdisi SM; Danesh NM; Ramezani M; Lavaee P; Jalalian SH; Robati RY; Abnous K
Eur J Pharm Biopharm; 2016 May; 102():152-8. PubMed ID: 26987703
[TBL] [Abstract][Full Text] [Related]
24. Co-Delivery of Epirubicin and siRNA Using Functionalized Mesoporous Silica Nanoparticles Enhances In vitro and In vivo Drug Efficacy.
Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Abnous K; Malaekeh-Nikouei B
Curr Drug Deliv; 2016; 13(7):1176-1182. PubMed ID: 26718488
[TBL] [Abstract][Full Text] [Related]
25. MUC1 aptamer conjugated to chitosan nanoparticles, an efficient targeted carrier designed for anticancer SN38 delivery.
Sayari E; Dinarvand M; Amini M; Azhdarzadeh M; Mollarazi E; Ghasemi Z; Atyabi F
Int J Pharm; 2014 Oct; 473(1-2):304-15. PubMed ID: 24905777
[TBL] [Abstract][Full Text] [Related]
26. Improved anticancer efficacy of epirubicin by magnetic mesoporous silica nanoparticles: in vitro and in vivo studies.
Ansari L; Jaafari MR; Bastami TR; Malaekeh-Nikouei B
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):594-606. PubMed ID: 29688064
[TBL] [Abstract][Full Text] [Related]
27. Ofloxacin@Doxorubicin-Epirubicin functionalized MCM-41 mesoporous silica-based nanocarriers as synergistic drug delivery tools for cancer related bacterial infections.
Galhano J; Marcelo GA; Duarte MP; Oliveira E
Bioorg Chem; 2022 Jan; 118():105470. PubMed ID: 34814085
[TBL] [Abstract][Full Text] [Related]
28. Targeted co-delivery of epirubicin and NAS-24 aptamer to cancer cells using selenium nanoparticles for enhancing tumor response in vitro and in vivo.
Jalalian SH; Ramezani M; Abnous K; Taghdisi SM
Cancer Lett; 2018 Mar; 416():87-93. PubMed ID: 29253524
[TBL] [Abstract][Full Text] [Related]
29. Surface decorated nanoparticles as surrogate carriers for improved transport and absorption of epirubicin across the gastrointestinal tract: Pharmacokinetic and pharmacodynamic investigations.
Tariq M; Alam MA; Singh AT; Panda AK; Talegaonkar S
Int J Pharm; 2016 Mar; 501(1-2):18-31. PubMed ID: 26812610
[TBL] [Abstract][Full Text] [Related]
30. Targeted rod-shaped mesoporous silica nanoparticles for the co-delivery of camptothecin and survivin shRNA in to colon adenocarcinoma in vitro and in vivo.
Babaei M; Abnous K; Taghdisi SM; Taghavi S; Sh Saljooghi A; Ramezani M; Alibolandi M
Eur J Pharm Biopharm; 2020 Nov; 156():84-96. PubMed ID: 32882423
[TBL] [Abstract][Full Text] [Related]
31. Preparation, characterization and evaluation of antibacterial properties of epirubicin loaded PHB and PHBV nanoparticles.
Perveen K; Masood F; Hameed A
Int J Biol Macromol; 2020 Feb; 144():259-266. PubMed ID: 31821825
[TBL] [Abstract][Full Text] [Related]
32. Improved antitumor activity and reduced cardiotoxicity of epirubicin using hepatocyte-targeted nanoparticles combined with tocotrienols against hepatocellular carcinoma in mice.
Nasr M; Nafee N; Saad H; Kazem A
Eur J Pharm Biopharm; 2014 Sep; 88(1):216-25. PubMed ID: 24813390
[TBL] [Abstract][Full Text] [Related]
33. Improving anti-cancer drug delivery performance of magnetic mesoporous silica nanocarriers for more efficient colorectal cancer therapy.
Iranpour S; Bahrami AR; Nekooei S; Sh Saljooghi A; Matin MM
J Nanobiotechnology; 2021 Oct; 19(1):314. PubMed ID: 34641857
[TBL] [Abstract][Full Text] [Related]
34. Mechanism Investigation of Hyaluronidase-Combined Multistage Nanoparticles for Solid Tumor Penetration and Antitumor Effect.
Chen E; Han S; Song B; Xu L; Yuan H; Liang M; Sun Y
Int J Nanomedicine; 2020; 15():6311-6324. PubMed ID: 32922003
[TBL] [Abstract][Full Text] [Related]
35. Enhanced cancer therapy with pH-dependent and aptamer functionalized doxorubicin loaded polymeric (poly D, L-lactic-co-glycolic acid) nanoparticles.
Saravanakumar K; Hu X; Shanmugam S; Chelliah R; Sekar P; Oh DH; Vijayakumar S; Kathiresan K; Wang MH
Arch Biochem Biophys; 2019 Aug; 671():143-151. PubMed ID: 31283911
[TBL] [Abstract][Full Text] [Related]
36. Folate conjugation improved uptake and targeting of porous hydroxyapatite nanoparticles containing epirubicin to cancer cells.
Ansari L; Derakhshi M; Bagheri E; Shahtahmassebi N; Malaekeh-Nikouei B
Pharm Dev Technol; 2020 Jun; 25(5):601-609. PubMed ID: 32026739
[TBL] [Abstract][Full Text] [Related]
37. Pullulan acetate nanoparticles prepared by solvent diffusion method for epirubicin chemotherapy.
Zhang HZ; Gao FP; Liu LR; Li XM; Zhou ZM; Yang XD; Zhang QQ
Colloids Surf B Biointerfaces; 2009 Jun; 71(1):19-26. PubMed ID: 19186037
[TBL] [Abstract][Full Text] [Related]
38. Epirubicin-loaded marine carrageenan oligosaccharide capped gold nanoparticle system for pH-triggered anticancer drug release.
Chen X; Han W; Zhao X; Tang W; Wang F
Sci Rep; 2019 May; 9(1):6754. PubMed ID: 31043709
[TBL] [Abstract][Full Text] [Related]
39. Lipid nanoparticle-based co-delivery of epirubicin and BCL-2 siRNA for enhanced intracellular drug release and reversing multidrug resistance.
Yu M; Han S; Kou Z; Dai J; Liu J; Wei C; Li Y; Jiang L; Sun Y
Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):323-332. PubMed ID: 28393563
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapeutic drug-photothermal agent co-self-assembling nanoparticles for near-infrared fluorescence and photoacoustic dual-modal imaging-guided chemo-photothermal synergistic therapy.
Li Y; Liu G; Ma J; Lin J; Lin H; Su G; Chen D; Ye S; Chen X; Zhu X; Hou Z
J Control Release; 2017 Jul; 258():95-107. PubMed ID: 28501673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
